ARTICLES BY KAMILA NOVAK
Should We Build Or Break Skill Silos In Clinical Trials?1/25/2022
We tend to forget to talk about the knowledge and skill silos in clinical trials that we have built over the years. This article describes how the industry got to where we are with narrow specialization and recommends 5 strategies to break skill silos.
Data Interoperability: The First Step To Leverage ML & AI In Clinical Trials12/9/2021
The first hurdle we need to overcome to leverage machine learning and AI in clinical development is data interoperability. We must break data silos, find a way to make the data points communicate with one another within the drug development continuum, and analyze each data point in its full context. This article also delves into the importance of metadata and the differences between different data formats.
Best Practices for Risk Assessment of GxP Vendors and Inspection Readiness9/21/2021
Requirements for risk management in clinical trials are outlined in GCP (R2) and provide you, as the sponsor, with the main steps for risk management in your studies. The implementation will vary from vendor to vendor depending on their delegated duties and functions. In addition to that, there are three other important considerations.
What Risk-Based Oversight Of GxP Vendors Is & Is Not In Clinical Trials9/2/2021
Some pharmaceutical companies still have a notion that delegating responsibility for a clinical trial to a vendor is a way to transfer risks related to the delegated duties and functions. Nothing is further from the truth. This article examines what is vendor oversight in the context of ICH's GCP (R2) guideline.